BRRGF:OTC-BerGenBio ASA (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 2.95

Change

0.00 (0.00)%

Market Cap

USD 0.28B

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

BerGenBio ASA, a clinical-stage biopharmaceutical company, develops medicines to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bioavailable small molecule AXL inhibitor, which is in Phase II clinical development in two major cancer indications. The Phase II clinical trial program focuses on lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as melanoma and triple negative breast cancer. In addition, it is developing tilvestamab, a function blocking antibody that is in Phase I clinical trial; and BGB601, a Phase I clinical trial antibody drug conjugate against human AXL that is linked to a cytotoxin. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was founded in 2007 and is headquartered in Bergen, Norway.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

-0.66 (-0.99%)

USD152.23B 27.18 2.70
CSLLY CSL Limited

-1.97 (-1.72%)

USD104.10B 46.54 27.25
CMXHF CSL Limited

N/A

USD104.10B 50.12 27.25
GNMSF Genmab A/S

+11.90 (+3.28%)

USD23.59B 101.26 2.65
UCBJY UCB SA

-1.04 (-1.90%)

USD20.60B 23.17 17.71
UCBJF UCB SA

N/A

USD20.60B 23.96 17.71
SBMFF Sino Biopharmaceutical Limited

N/A

USD20.37B 31.52 3.18
SBHMY Sino Biopharmaceutical Limited

N/A

USD18.59B 52.10 3.18
PPTDF PeptiDream Inc

N/A

USD6.03B 260.99 1.61
ABCZY Abcam plc

+0.55 (+2.98%)

USD4.35B 236.08 106.86

ETFs Containing BRRGF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 84.38% 71% C- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 84.38% 71% C- 81% B-
Trailing 12 Months  
Capital Gain 84.38% 73% C 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 84.38% 73% C 81% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -7.70% N/A N/A 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.70% N/A N/A 22% F
Risk Return Profile  
Volatility (Standard Deviation) 61.22% N/A N/A 35% F
Risk Adjusted Return -12.58% N/A N/A 33% F
Market Capitalization 0.28B 81% B- 62% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.95 66% D 34% F
Price / Cash Flow Ratio -1.52 42% F 69% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -47.26% 52% F 19% F
Return on Invested Capital -73.38% 25% F 11% F
Return on Assets -28.08% 62% D- 24% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 2.04 15% F 19% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector